1 Curzon Street
19 articles with Stallergenes Greer
Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, and Alyatec, a contract research organisation based in Strasbourg University Hospital, announced that they have entered into a collaboration to advance precision medicine in AIT.
Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
Stallergenes Greer announces that Alustal®, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).
Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite allergen immunotherapy tablet Actair®.
Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today
Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
Stallergenes Greer and Anergis Report Successful Preclinical Study Results With COP-virosomes as Second-generation Allergen Immunotherapy
Stallergenes Greer, a worldwide leader in allergen immunotherapy and Anergis, a leader in ultra-fast AIT research and development, announced the results of a joint research study evaluating the effects of second-generation Contiguous Overlapping Peptides allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.
Stallergenes Greer: Expands Supply of Subcutaneous Products; Sustains Investment in Quality and Operational Excellence
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products, further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
Stallergenes Greer Submits a Marketing Authorisation Application in Europe for Its Sublingual House Dust Mite Allergen Immunotherapy Tablet
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the submission of a marketing authorisation application for STAGR320, its sublingual house dust mite immunotherapy tablet, via a European decentralized procedure.
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
Stallergenes Greer and Anergis Initiate New Study to Predict Efficacy of Second-Generation Allergen Immunotherapy
Second-generation Allergen Immunotherapy based on Anergis Contiguous Overlapping Peptides (COP) linked to Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch pollen allergy.
Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial
Stallergenes Greer announced that house dust mite induced allergic rhinitis, its treatment with sublingual tablets and the benefits of allergen immunotherapy for patients will be presented at the annual EAACI Congress to be held in Lisbon from June 1-5 2019.
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
The study achieved its primary efficacy endpoint (p<0.0001)
Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair® Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy
Stallergenes Greer today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the extension of the indication for Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract), an allergy immunotherapy sublingual tablet, to treat patients ages five to nine with grass pollen-induced allergic rhinitis.
Company now expects 2018 net sales to be in the range of €270 million to €280 million and EBITDA to be in the range of €40 million to €50 million.
Stallergenes Greer plc: Two New Real-World Evidence Studies Show Long-Term Benefits of Sublingual Allergy Immunotherapy
Stallergenes Greer announced positive results from two real-world evidence studies regarding the use of allergy immunotherapy (AIT) compared to the use of only symptomatic treatments to treat patients with respiratory allergies.
Stallergenes Greer Reports Solid Growth and Continued Recovery in 2017, Delivering on Full Year Guidance
Stallergenes Greer announced its full year results for the year ended 31 December 2017.
Stallergenes Greer Announces Approval in Japan of Pediatric Use for ACTAIR, Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy
Stallergenes Greer announced that its partner in Japan, Shionogi & Co. Ltd., received approval for the extension of the indication for ACTAIR, an allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.
Stallergenes Greer Presents Findings From Four Allergy Immunotherapy Studies At The 2016 AAAAI Annual Meeting